D1.117 - Combing dual biologics therapy for severe asthma : a series of ten cases
Case report
Background: Biologic therapy has revolutionized the management of severe asthma, but a subset of patients with severe asthma exhibit uncontrolled symptoms potentially due to the involvement of multi-type 2 pathways. Dual biologic therapy has emerged as a promising strategy, but its efficacy and safety are not yet fully understood. The objective of this study is to describe the characteristics, endotyping features, decision-making process and therapeutic response of patients with severe asthma on dual biologic therapy in a real-world setting.
Methods: We present ten patients on dual biologics for severe asthma. The biologic combinations are the following; mepolizumab + dupilumab (n=7), benralizumab + dupilumab (n=1), and omazulab + mepolizumab (n=2). The mean duration of combination therapy used was 13.5 months. Therapeutic response was assessed by type 2 inflammation biomarkers, symptom control, frequency of acute exacerbations, daily oral corticosteroid (OCS) dosage and side effects.
Results: All ten patients exhibited good tolerance to the combined biologic therapies, leading to improvements in asthma and comorbidity management, and reduced OCS usage. No serious adverse events were reported.
Conclusion: Dual biologics are both effective and safe. However, more studies are needed to completely assess the long-term benefits and potential risks of different combinations of biologic treatments.
